MedTrace Logo

Nebulized Versus Intravenous Magnesium Sulfate in Treatment of Asthma Exacerbation

NCT05908864 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 123

Last updated 2023-06-18

No results posted yet for this study

Summary

A prospective study in Beni-Seuf University Hospital that was conducted on 123 adult patients with acute asthma exacerbations. Patients were classified into group (I): received IV magnesium sulfate, group (II): received nebulized magnesium sulfate, and group (III): control group. Blood pressure, respiratory rate, pulse, peak expiratory flow rate (PEFR) measurement using a peak flowmeter, Fischl index and need for hospitalization in patients with acute bronchial asthma were done for all patients before treatment, immediately after the treatment, "30", and "60" min after treatment.

Conditions

  • Asthma Attack

Interventions

DRUG

Magnesium sulfate

Blood pressure, respiratory rate, pulse, peak expiratory flow rate (PEFR) measurement using a peak flowmeter, Fischl index and need for hospitalization in patients with acute bronchial asthma were done

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-30
Primary Completion
2019-11-22
Completion
2020-12-15
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05908864 on ClinicalTrials.gov